Mazor Robotics Ltd. (MZOR) Receives $37.33 Average PT from Brokerages
Mazor Robotics Ltd. (NASDAQ:MZOR) has received an average rating of “Hold” from the ten ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $37.33.
Several equities research analysts have recently commented on MZOR shares. Ladenburg Thalmann Financial Services restated a “buy” rating and set a $46.00 price target on shares of Mazor Robotics in a research note on Monday, June 12th. Zacks Investment Research upgraded Mazor Robotics from a “sell” rating to a “buy” rating and set a $41.00 price target for the company in a research note on Tuesday, August 15th. Needham & Company LLC restated a “hold” rating on shares of Mazor Robotics in a research note on Wednesday, August 30th. ValuEngine upgraded Mazor Robotics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, B. Riley restated a “neutral” rating and set a $31.00 price target on shares of Mazor Robotics in a research note on Monday, May 15th.
Several institutional investors have recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC purchased a new stake in shares of Mazor Robotics during the second quarter worth approximately $2,421,000. Raymond James Financial Services Advisors Inc. purchased a new position in Mazor Robotics in the second quarter worth $770,000. Royal Bank of Canada raised its position in Mazor Robotics by 9.2% in the second quarter. Royal Bank of Canada now owns 21,663 shares of the medical instruments supplier’s stock worth $749,000 after acquiring an additional 1,819 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Mazor Robotics by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 8,570 shares of the medical instruments supplier’s stock worth $296,000 after acquiring an additional 641 shares in the last quarter. Finally, Messner & Smith Theme Value Investment Management Ltd. CA raised its position in Mazor Robotics by 23.6% in the second quarter. Messner & Smith Theme Value Investment Management Ltd. CA now owns 36,201 shares of the medical instruments supplier’s stock worth $1,252,000 after acquiring an additional 6,919 shares in the last quarter. Institutional investors and hedge funds own 27.52% of the company’s stock.
Shares of Mazor Robotics (NASDAQ MZOR) traded down 4.30% during trading on Tuesday, hitting $44.11. 459,712 shares of the company traded hands. The stock’s market capitalization is $1.06 billion. Mazor Robotics has a 52-week low of $20.19 and a 52-week high of $49.64. The company has a 50-day moving average of $40.10 and a 200-day moving average of $34.91.
Mazor Robotics (NASDAQ:MZOR) last issued its quarterly earnings data on Tuesday, August 1st. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.09. Mazor Robotics had a negative return on equity of 28.51% and a negative net margin of 37.66%. The company had revenue of $15.46 million during the quarter, compared to analysts’ expectations of $15.38 million. During the same quarter in the previous year, the business earned ($0.09) earnings per share. The firm’s revenue for the quarter was up 86.7% on a year-over-year basis. Equities analysts expect that Mazor Robotics will post ($0.74) EPS for the current year.
About Mazor Robotics
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Stock Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related stocks with our FREE daily email newsletter.